HomeBUSINESS
BUSINESS

Growth of Global Products Outstrips Abilify Drop in Jan.-June: Otsuka
(Aug.9.2017)

Otsuka Holdings President Tatsuo Higuchi
Otsuka Holdings saw its pharmaceutical revenue inch up 0.8% year on year to 373,761 million yen in the first half of 2017 as shriveling sales of Abilify (aripiprazole), the company’s flagship antipsychotic hit by a patent loss, were countered by growth of newer global products ...
(LOG IN FOR FULL STORY)

News Calendar